moxifloxacin has been researched along with Lung Neoplasms in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Bian, S; Lei, W; Tang, X | 1 |
Chen, W; Cheng, NC; Fang, G; Hu, CM; Huang, LL; Xie, WP | 1 |
Bulcun, E; Çimen, D; Ekici, A; Ekici, M; Güngör, Ö | 1 |
Becker, J; Chatzikyrkou, C; Clajus, C; Hafer, C; Hamwi, I; Kielstein, JT | 1 |
Arvis, P; Breilh, D; Djabarouti, S; Gordien, JB; Jougon, J; Landreau, V; Saux, MC; Velly, JF; Xuereb, F | 1 |
1 review(s) available for moxifloxacin and Lung Neoplasms
Article | Year |
---|---|
The first report of co-existence of pulmonary tuberculosis and lung malignancy in a kidney transplant recipient: a case report and literature review.
Topics: Adenocarcinoma; China; Ethambutol; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Isoniazid; Kidney Transplantation; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Positron Emission Tomography Computed Tomography; Thoracic Surgery, Video-Assisted; Treatment Outcome; Tuberculosis, Pulmonary | 2021 |
1 trial(s) available for moxifloxacin and Lung Neoplasms
Article | Year |
---|---|
Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
Topics: Administration, Oral; Adult; Antibiotic Prophylaxis; Aza Compounds; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infusions, Intravenous; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Postoperative Complications; Prospective Studies; Quinolines; Reference Values; Risk Factors; Tissue Distribution; Treatment Outcome | 2003 |
3 other study(ies) available for moxifloxacin and Lung Neoplasms
Article | Year |
---|---|
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin.
Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Male; Moxifloxacin; Mutation; Protein Kinase Inhibitors; Torsades de Pointes | 2020 |
Case of round pneumonia: pulmonary infarct and a rare situation that is similar with the lung cancer.
Topics: Diagnosis, Differential; Fluoroquinolones; Humans; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Pneumonia; Pulmonary Infarction; Radiography, Thoracic; Treatment Outcome; Young Adult | 2015 |
Biopsy proven acute interstitial nephritis after treatment with moxifloxacin.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Biopsy; Carcinoma, Non-Small-Cell Lung; Creatinine; Edema; Eosinophilia; Fluoroquinolones; Humans; Lung Neoplasms; Male; Moxifloxacin; Nephritis, Interstitial; Pneumonectomy; Pneumonia; Postoperative Complications; Prednisolone; Quinolines | 2010 |